Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
  • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
  • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
  • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
  • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
  • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/04—Anorexiants; Antiobesity agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• Cardiovascular disease is one of the leading causes of death in the United States and most European countries. It is estimated that over 70 million people in the United States alone suffer from a cardiovascular disease or disorder including but not limited to high blood pressure, coronary heart disease, dyslipidemia, congestive heart failure and stroke.
• Lovaza® a lipid regulating agent
• Lovaza® a lipid regulating agent
• Lovaza® can significantly increase LDL-C and/or non-HDL-C levels in some patients.
• the present invention provides methods of reducing the risk of a cardiovascular event in a subject on statin therapy.
• the method comprises administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
• the subject has a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL.
• the composition contains not more than 10%, by weight, docosahexaenoic acid or derivative thereof, substantially no docosahexaenoic acid or derivative thereof, or no docosahexaenoic acid or derivative thereof.
• eicosapentaenoic acid ethyl ester comprises at least 96%, by weight, of all fatty acids present in the composition; the composition contains not more than 4%, by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester; and/or the composition contains about 0.1% to about 0.6% of at least one fatty acid other than eicosapentaenoic acid ethyl ester and docosahexaenoic acid.
• the invention provides a method of treating hypertriglyceridemia comprising administering a composition as described herein to a subject in need thereof one to about four times per day.
• a composition of the invention is administered to a subject in an amount sufficient to provide a daily dose of eicosapentaenoic acid of about 1 mg to about 10,000 mg, 25 about 5000 mg, about 50 to about 3000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about
• a composition for use in methods of the invention comprises eicosapentaenoic acid, or a pharmaceutically acceptable ester, derivative, conjugate or salt thereof, or mixtures of any of the foregoing, collectively referred to herein as "EPA.”
• EPA eicosapentaenoic acid
• pharmaceutically acceptable in the present context means that the substance in question does not produce unacceptable toxicity to the subject or interaction with other components of the composition.
• the EPA comprises an eicosapentaenoic acid ester.
• the EPA comprises a Ci - C5 alkyl ester of eicosapentaenoic acid.
• the EPA comprises eicosapentaenoic acid ethyl ester, eicosapentaenoic acid methyl ester, eicosapentaenoic acid propyl ester, or
• the EPA is in the form of ethyl-EPA, lithium EPA, mono-, di- or triglyceride EPA or any other ester or salt of EPA, or the free acid form of EPA.
• the EPA may also be in the form of a 2-substituted derivative or other derivative which slows down its rate of oxidation but does not otherwise change its biological action to any substantial degree.
• EPA is present in a composition useful in accordance with methods of the invention in an amount of about 50 mg to about 5000 mg, about 75 mg to about 2500 mg, or about 100 mg to about 1000 mg, for example about 75 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 225 mg, about 250 mg, about 275 mg, about 300 mg, about 325 mg, about 350 mg, about 375 mg, about 400 mg, about 425 mg, about 450 mg, about 475 mg, about 500 mg, about 525 mg, about 550 mg, about 575 mg, about 600 mg, about 625 mg, about 650 mg, about 675 mg, about 700 mg, about 725 mg, about 750 mg, about 775 mg, about 800 mg, about 825 mg, about 850 mg, about 875 mg, about 900 mg, about 925 mg, about 950 mg, about 975 mg, about 1000 mg, about 1025 mg, about 1050 mg, about 1075 mg, about 1100 mg,
• a composition useful in accordance with the invention contains not more than about 10%, not more than about 9%, not more than about 8%, not more than about 7%, not more than about 6%, not more than about 5%, not more than about 4%, not more than about 3%, not more than about 2%, not more than about 1%, or not more than about 0.5%, by weight, docosahexaenoic acid (DHA), if any.
• DHA docosahexaenoic acid
• a composition of the invention contains substantially no docosahexaenoic acid.
• a composition useful in the present invention contains no docosahexaenoic acid and/or derivative thereof.
• EPA comprises at least 70%, at least 80%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, by weight, of all fatty acids present in a composition that is useful in methods of the present invention.
• the composition comprises at least 96% by weight of eicosapentaenoic acid ethyl ester and less than about 2% by weight of a preservative.
• the preservative is a tocopherol such as all-racemic a- tocopherol.
• a composition useful in accordance with methods of the invention contains less than 10%, less than 9%, less than 8%, less than 7%, less than 6%, less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.5% or less than 0.25%, by weight of the total composition or by weight of the total fatty acid content, of any fatty acid other than EPA.
• fatty acid other than EPA examples include linolenic acid (LA), arachidonic acid (AA), docosahexaenoic acid (DHA), alpha-linolenic acid (ALA), stearadonic acid (STA), eicosatrienoic acid (ETA) and/or docosapentaenoic acid (DP A).
• a composition useful in accordance with methods of the invention contains about 0.1% to about 4%, about 0.5% to about 3%, or about 1% to about 2%, by weight, of total fatty acids other than EPA and/or DHA.
• a composition useful in accordance with the invention has one or more of the following features: (a) eicosapentaenoic acid ethyl ester represents at least about 96%, at least about 97%, or at least about 98%, by weight, of all fatty acids present in the composition; (b) the composition contains not more than about 4%, not more than about 3%, or not more than about 2%, by weight, of total fatty acids other than eicosapentaenoic acid ethyl ester; (c) the composition contains not more than about 0.6%, not more than about 0.5%, or not more than about 0.4% of any individual fatty acid other than eicosapentaenoic acid ethyl ester; (d) the composition has a refractive index (20 °C) of about 1 to about 2, about 1.2 to about 1.8 or about 1.4 to about 1.5; (e) the composition has a specific gravity (20 °C) of about 0.8 to about
• compositions useful in accordance with methods of the invention are orally deliverable.
• oral administration include any form of delivery of a therapeutic agent or a composition thereof to a subject wherein the agent or composition is placed in the mouth of the subject, whether or not the agent or composition is swallowed.
• oral administration includes buccal and sublingual as well as esophageal administration.
• the composition is present in a capsule, for example a soft gelatin capsule.
• a composition for use in accordance with the invention can be formulated as one or more dosage units.
• dose unit and “dosage unit” herein refer to a portion of a pharmaceutical composition that contains an amount of a therapeutic agent suitable for a single administration to provide a therapeutic effect.
• dosage units may be administered one to a plurality (i.e. 1 to about 10, 1 to 8, 1 to 6, 1 to 4 or 1 to 2) of times per day, or as many times as needed to elicit a therapeutic response.
• compositions of the invention upon storage in a closed container maintained at room temperature, refrigerated (e.g. about 5 to about 5 -10 °C) temperature, or frozen for a period of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1, or 12 months, exhibit at least about 90%, at least about 95%, at least about 97.5%, or at least about 99% of the active ingredient(s) originally present therein.
• the invention provides a method for treatment and/or prevention of cardiovascular-related disease and disorders.
• cardiovascular-related disease and disorders refers to any disease or disorder of the heart or blood vessels (i.e. arteries and veins) or any symptom thereof.
• cardiovascular-related disease and disorders include hypertriglyceridemia, hypercholesterolemia, mixed dyslipidemia, coronary heart disease, vascular disease, stroke, atherosclerosis, arrhythmia, hypertension, myocardial infarction, and other cardiovascular events.
• treatment in relation a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the
• prevention in relation to a given disease or disorder means: preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
• the present invention provides methods of reducing a risk of a cardiovascular event in a subject on statin therapy.
• the method comprises (a) identifying a subject on statin therapy and having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, wherein said subject has established cardiovascular disease or has a high risk of developing cardiovascular disease; and (b) administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester per day, wherein the composition contains substantially no docosahexaenoic acid.
• the subject has a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, for example 135 mg/dL to 500 mg/dL, 150 mg/dL to 500 mg/dL, or 200 mg/dL to ⁇ 500 mg/dL.
• the subject or subject group has a baseline triglyceride level (or median baseline triglyceride level in the case of a subject group), fed or fasting, of about 135 mg/dL, about 140 mg/dL, about 145 mg/dL, about 150 mg/dL, about 155 mg/dL, about 160 mg/dL, about 165 mg/dL, about 170 mg/dL, about 175 mg/dL, about 180 mg/dL, about 185 mg/dL, about 190 mg/dL, about 195 mg/dL, about 200 mg/dL, about 205 mg/dL, about 210 mg/dL, about 215 mg/dL, about 220 mg/dL, about 225 mg/dL, about 230 mg/dL, about 235 mg/dL, about 240 mg/dL, about 245 mg/dL, about 250 mg/dL, about 255 mg/dL, about 260 mg/dL, about 265 mg/d
• the subject or subject group is also on stable therapy with a statin (with or without ezetimibe).
• the subject or subject group also has established cardiovascular disease, or is at high risk for establishing cardiovascular disease.
• the subject's statin therapy includes administration of one or more statins.
• the subject's statin therapy may include one or more of: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin.
• the subject is additionally administered one or more of: amlodipine, ezetimibe, niacin, and sitagliptin.
• the subject's statin therapy includes administration of a statin and ezetimibe.
• the subject's statin therapy includes administration of a statin without ezetimibe.
• the subject's statin therapy does not include administration of 200 mg or more per day of niacin and/or fibrates.
• the subject is not on concomitant omega-3 fatty acid therapy (e.g., is not being administered or co-administered a prescription and/or over-the-counter composition comprising an omega-3 fatty acid active agent).
• the subject is not administered or does not ingest a dietary supplement comprising an omega-3 fatty acid.
• the subject has established cardiovascular disease ("CV disease” or "CVD”).
• CV disease cardiovascular disease
• the status of a subject as having CV disease can be determined by any suitable method known to those skilled in the art.
• a subject is identified as having established CV disease by the presence of any one of: documented coronary artery disease, documented cerebrovascular disease, documented carotid disease, documented peripheral arterial disease, or combinations thereof.
• a subject is identified as having CV disease if the subject is at least 45 years old and: (a) has one or more stenosis of greater than 50% in two major epicardial coronary arteries; (b) has had a documented prior MI; (c) has been hospitalized for high-risk NSTE ACS with objective evidence of ischemia (e.g., ST-segment deviation and/or biomarker positivity); (d) has a documented prior ischemic stroke; (e) has symptomatic artery disease with at least 50% carotid arterial stenosis; (f) has asymptomatic carotid artery disease with at least 70% carotid arterial stenosis per angiography or duplex ultrasound; (g) has an ankle- brachial index ("ABI") of less than 0.9 with symptoms of intermittent claudication; and/or (h) has a history of aorto-iliac or peripheral arterial intervention (catheter-based or surgical).
• ABSI ankle- brachial index
• the subject or subject group being treated in accordance with methods of the invention has a high risk for developing CV disease.
• a subject or subject group has a high risk for developing CV disease if the subject or subject in a subject group is age 50 or older, has diabetes mellitus (Type 1 or Type 2), and at least one of: (a) is a male age 55 or older or a female age 65 or older; (b) is a cigarette smoker or was a cigarette smoker who stopped less than 3 months prior; (c) has hypertension (e.g., a blood pressure of 140 mmHg systolic or higher, or greater than 90 mmHg diastolic); (d) has an HDL-C level of ⁇ 40 mg/dL for men or ⁇ 50 mg/dL for women; (e) has an hs-CRP level of > 3.0 mg/L; (f) has renal dysfunction (e.g., a creatinine clearance ("CrCL”) of
• the subject's baseline lipid profile is measured or determined prior to administering the pharmaceutical composition to the subject.
• Lipid profile characteristics can be determined by any suitable method known to those skilled in the art including, for example, by testing a fasting or non-fasting blood sample obtained from the subject using standard blood lipid profile assays.
• the subject has one or more of: a baseline non-HDL-C value of about 200 mg/dL to about 300 mg/dL; a baseline total cholesterol value of about 250 mg/dL to about 300 mg/dL; a baseline VLDL-C value of about 140 mg/dL to about 200 mg/dL; a baseline HDL-C value of about 10 to about 30 mg/dL; and/or a baseline LDL-C value of about 40 to about 100 mg/dL.
• the cardiovascular event for which risk is reduced is one or more of: cardiovascular death; nonfatal myocardial infarction; nonfatal stroke; coronary revascularization; unstable angina (e.g., unstable angina determined to be caused by myocardial ischemia by, for example, invasive or non-invasive testing, and requiring hospitalization); cardiac arrest; peripheral cardiovascular disease requiring intervention, angioplasty, bypass surgery or aneurysm repair; death; and onset of new congestive heart failure.
• unstable angina e.g., unstable angina determined to be caused by myocardial ischemia by, for example, invasive or non-invasive testing, and requiring hospitalization
• cardiac arrest e.g., unstable angina determined to be caused by myocardial ischemia by, for example, invasive or non-invasive testing, and requiring hospitalization
• cardiac arrest e.g., unstable angina determined to be caused by myocardial ischemia by, for example, invasive or non-invasive testing, and requiring hospitalization
• the subject is administered about 1 g to about 4 g of the pharmaceutical composition per day for about 4 months, about 1 year, about 2 years, about 3 years, about 4 years, about 5 years, or more than about 5 years.
• the subject exhibits one or more of
• the subject exhibits one or more of: (a) a reduction in triglyceride level of at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, or at least about 55% as compared to baseline;
• the subject or subject group being treated has a baseline EPA blood level on a (mol%) basis of less than 2.6 , less than 2.5, less than 2.4, less than 2.3, less than 2.2, less than 2.1, less than 2, less than 1.9, less than 1.8, less than 1.7, less than 1.6, less than 1.5, less than 1.4, less than 1.3, less than 1.2, less than 1.1 or less than 1.
• the subject or subject group being treated has a baseline triglyceride level (or median baseline triglyceride level in the case of a subject group), fed or fasting, of about 135 mg/dL to about
• the subject or subject group being treated in accordance with methods of the invention is on stable therapy with a statin (with or without ezetimibe).
• a statin with or without ezetimibe.
• the phrase "on stable therapy with a statin” means that the subject or subject group has been on the same daily dose of the same statin for at least 28 days and, if applicable, the same daily dose of ezetimibe for at least 28 days.
• the subject or subject group on stable statin therapy has an LDL-C level of about 40 mg/dL to about 100 mg/dL.
• safety laboratory tests of subject blood samples include one or more of: hematology with complete blood count (“CBC"), including RBC, hemoglobin (Hgb), hematocrit (Hct), white cell blood count (WBC), white cell differential, and platelet count; and biochemistry panel including total protein, albumin, alkaline phosphatase, alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), total bilirubin, glucose, calcium, electrolytes, (sodium, potassium, chloride), blood urea nitrogen (BUN), serum creatinine, uric acid, creatine kinase, and HbAi c .
• CBC hematology with complete blood count
• Hgb hemoglobin
• Hct hematocrit
• WBC white cell blood count
• platelet count and platelet count
• biochemistry panel including total protein, albumin, alkaline phosphatase, alanine aminotransferase
• a fasting lipid panel associated with a subject includes TG, TC, LDL-C, HDL-C, non-HDL-C, and VLDL-C.
• LDL-C is calculated using the Friedewald equation, or is measured by preparative ultracentrifugation (Beta Quant) if the subject's triglyceride level is greater than 400 mg/dL.
• LDL-C is measured by ultracentrifugation (Beta Quant) at randomization and again after about one year after randomization.
• a biomarker assay associated with blood obtained from a subject includes hs-CRP, Apo B and hsTnT.
• a medical history associated with a subject includes family history, details regarding all illnesses and allergies including, for example, date(s) of onset, current status of condition(s), and smoking and alcohol use.
• demographic information associated with a subject includes day, month and year of birth, race, and gender.
• vital signs associated with a subject include systolic and diastolic blood pressure, heart rate, respiratory rate, and body temperature (e.g., oral body temperature).
• a physical examination of a subject includes assessments of the subject's general appearance, skin, head, neck, heart, lung, abdomen, extremities, and neuromusculature.
• the subject's height and weight are measured. In some embodiments, the subject's weight is recorded with the subject wearing indoor clothing, with shoes removed, and with the subject's bladder empty.
• a waist measurement associated with the subject is measured.
• the waist measurement is determined with a tape measure at the top of the subject's hip bone.
• an electrocardiogram associated with the subject is obtained.
• an ECG is obtained every year during the treatment/follow-up portion of the study.
• the ECG is a 12-lead ECG.
• the ECG is analyzed for detection of silent MI.
• subjects randomly assigned to the treatment group receive 4 g per day of a composition comprising at least 96% by weight of eicosapentaenoic acid ethyl ester.
• the composition is encapsulated in a gelatin capsule.
• subjects in this treatment group continue to take 4 g per day of the composition for about 1 year, about 2 years, about 3 years, about 4 years, about 4.75 years, about 5 years, about 6 years, about 7 years, about 8 years, about 9 years, about 10 years, or more than about 10 years.
• a median treatment duration is planned to be about 4 years.
• the present invention provides a method of reducing a risk of cardiovascular events in a subject.
• the method comprises administering to the subject a composition comprising at least 96% by weight of eicosapentaenoic acid ethyl ester.
• the subject is administered about 1 g to about 4 g of the composition per day.
• the reduced risk of CV events is indicated or determined by comparing an amount of time (e.g., an average amount of time) associated with a subject or subject group from first dosing to a first CV event selected from the group consisting of: CV death, nonfatal MI, nonfatal stroke, coronary revascularization, and hospitalization (e.g., emergent hospitalization) for unstable angina determined to be caused by myocardial ischemia (e.g., by invasive or noninvasive testing), to an amount of time (e.g., an average amount of time) associated with a placebo or untreated subject or group of subjects from first dosing with a placebo to a first CV event selected from the group consisting of: CV death, nonfatal MI, nonfatal stroke, coronary revascularization, and hospitalization (e.g., emergent hospitalization) for unstable angina determined to be caused by myocardial ischemia (e.g., by invasive or non-invasive testing), wherein said placebo does not
• the amount of time associated with the subject or group of subjects are compared to the amount of time associated with the placebo or untreated subject or group of subjects are compared using a log-rank test.
• the log-rank test includes one or more stratification factors such as CV Risk Category, use of ezetimibe, and/or geographical region.
• the present invention provides a method of reducing risk of CV death in a subject on stable statin therapy and having CV disease or at high risk for developing CV disease, comprising administering to the subject a composition as disclosed herein.
• the present invention provides a method of reducing risk of recurrent nonfatal myocardial infarction (including silent MI) in a subject on stable statin therapy and having CV disease or at high risk for developing CV disease, comprising administering to the patient one or more compositions as disclosed herein.
• the present invention provides a method of reducing risk of nonfatal stroke in a subject on stable statin therapy and having CV disease or at high risk for developing CV disease, comprising administering to the subject a composition as disclosed herein.
• the present invention provides a method of reducing risk of coronary revascularization in a subject on stable statin therapy and having CV disease or at high risk for developing CV disease, comprising administering to the subject a composition as disclosed herein.
• the present invention provides a method of reducing risk of developing unstable angina caused by myocardial ischemia in a subject on stable statin therapy and having CV disease or at high risk for developing CV disease, comprising administering to the subject a composition as disclosed herein.
• any of the methods disclosed herein are used in treatment or prevention of a subject or subjects that consume a traditional Western diet.
• the methods of the invention include a step of identifying a subject as a Western diet consumer or prudent diet consumer and then treating the subject if the subject is deemed a Western diet consumer.
• the term "Western diet” herein refers generally to a typical diet consisting of, by percentage of total calories, about 45% to about 50% carbohydrate, about 35% to about 40% fat, and about 10% to about 15% protein.
• a Western diet may alternately or additionally be characterized by relatively high intakes of red and processed meats, sweets, refined grains, and desserts, for example more than 50%, more than 60% or more or 70% of total calories come from these sources.
• a composition as described herein is administered to a subject once or twice per day.
• 1, 2, 3 or 4 capsules, each containing about 1 g of a composition as described herein are administered to a subject daily.
• 1 or 2 capsules, each containing about 1 g of a composition as described herein are administered to the subject in the morning, for example between about 5 am and about 1 1 am, and 1 or 2 capsules, each containing about 1 g of a composition as described herein, are administered to the subject in the evening, for example between about 5 pm and about 11 pm.
• the risk of a cardiovascular event in a subject is reduced compared to a control population.
• a plurality of control subjects to a control population wherein each control subject is on stable statin therapy, has a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL, and has established cardiovascular disease or a high risk of developing cardiovascular disease, and wherein the control subjects are not administered the pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester per day.
• a first time interval beginning at (a) an initial administration of a composition as disclosed herein to the subject to (b) a first cardiovascular event of the subject is greater than or substantially greater than a first control time interval beginning at (a') initial administration of a placebo to the control subjects to (b') a first cardiovascular event in the control subjects.
• the first cardiovascular event of the subject is a major cardiovascular event selected from the group consisting of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina caused by myocardial ischemia.
• the first cardiovascular event of the control subjects is a major cardiovascular event selected from the group consisting of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina caused by myocardial ischemia.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is any of: death (from any cause), nonfatal myocardial infarction, or nonfatal stroke.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is any of: death from a cardiovascular cause, nonfatal myocardial infarction, coronary
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is any of: death from a cardiovascular cause, nonfatal myocardial infarction, and coronary revascularization, unstable angina.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is any of: death from a cardiovascular cause and nonfatal myocardial infarction.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is death (from any cause).
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is any of: fatal myocardial infarction and nonfatal myocardial infarction (optionally including silent MI).
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is coronary revascularization.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is hospitalization (e.g.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is any one of: fatal stroke or nonfatal stroke.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is any one of: new coronary heart failure, new coronary heart failure leading to hospitalization, transient ischemic attack, amputation for coronary vascular disease, and carotid
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is any one of: elective coronary revascularization and emergent coronary revascularization.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is an onset of diabetes.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is cardiac arrhythmia requiring hospitalization.
• the first cardiovascular event of the subject and the first cardiovascular event of the control subjects is cardiac arrest.
• a second time interval beginning at (a) an initial administration of the pharmaceutical composition to the subject to (c) a second cardiovascular event of the subject is greater than or substantially greater than a second control time interval beginning at (a') initial administration of a placebo to the control subjects to (c') a second cardiovascular event in the control subjects.
• the second cardiovascular event of the subject and the second cardiovascular event of the control subjects is a major cardiovascular event selected from the group consisting of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and unstable angina caused by myocardial ischemia.
• the subject has diabetes mellitus and the control subjects each have diabetes mellitus.
• the subject has metabolic syndrome and the control subjects each have metabolic syndrome.
• the subject exhibits one or more of (a) reduced triglyceride levels compared to the control population; (b) reduced Apo B levels compared to the control population; (c) increased HDL-C levels compared to the control population; (d) no increase in LDL-C levels compared to the control population; (e) a reduction in LDL-C levels compared to the control population; (f) a reduction in non-HDL-C levels compared to the control population; (g) a reduction in VLDL levels compared to the control population; (h) a reduction in total cholesterol levels compared to the control population; (i) a reduction in high sensitivity C-reactive protein (hs-CRP) levels compared to the control population; and/or (j) a reduction in high sensitivity troponin (hsTnT) levels compared to the control population.
• hs-CRP high sensitivity C-reactive protein
• the subject's weight after administration of the composition is less than a baseline weight determined before administration of the composition. In some embodiments, the subject's waist circumference after administration of the composition is less than a baseline waist circumference determined before administration of the composition.
• the time interval may be for example an average, a median, or a mean time interval.
• the first control time interval is an average, a median, or a mean of a plurality of first control time intervals associated with each control subject.
• the second control time interval is an average, a median, or a mean of a plurality of second control time intervals associated with each control subject.
• the reduced risk of cardiovascular events is expressed as a difference in incident rates between a study group and a control population.
• the subjects in the study group experience a first major cardiovascular event after an initial administration of a composition as disclosed herein at a first incidence rate which is less than a second incidence rate, wherein the second incidence rate is associated with the rate of cardiovascular events in the subjects in the control population.
• the first major cardiovascular event after an initial administration of a composition as disclosed herein at a first incidence rate which is less than a second incidence rate, wherein the second incidence rate is associated with the rate of cardiovascular events in the subjects in the control population.
• the first major cardiovascular event after an initial administration of a composition as disclosed herein at a first incidence rate which is less than a second incidence rate, wherein the second incidence rate is associated with the rate of cardiovascular events in the subjects in the control population.
• the first major cardiovascular event after an initial administration of a composition as disclosed herein at a first incidence rate which is less than a second incidence rate, wherein the second incidence rate is associated with the rate of cardiovascular events
• cardiovascular event is any one of: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, and hospitalization for unstable angina (optionally determined to be caused by myocardial ischemia).
• the first and second incidence rates are determined for a time period beginning on the date of the initial administration and ending about 4 months, about 1 year, about 2 years, about 3 years, about 4 years, or about 5 years after the date of initial administration.
• the invention provides use of any composition described herein for treating hypertriglyceridemia in a subject in need thereof, comprising: providing a subject having a fasting baseline triglyceride level of about 135 mg/dL to about 500 mg/dL and administering to the subject a pharmaceutical composition as described herein.
• the composition comprises about 1 g to about 4 g of eicosapentaenoic acid ethyl ester, wherein the composition contains substantially no docosahexaenoic acid.
• a phase 3, multi-center, placebo-controlled randomized, double-blind, 12- week study with an open-label extension is performed to evaluate the efficacy and safety of AMR101 in patients with fasting triglyceride levels > 150 mg/dL and ⁇ 500 mg/dL.
• the primary objective is, in patients at LDL-C goal while on statin therapy, with established cardiovascular disease (CVD) or at high risk for CVD, and hypertriglyceridemia (fasting triglycerides, TG, >200 mg/dL and ⁇ 500 mg/dL, determine the efficacy of AMR101 4 g daily, compared to placebo, in preventing the occurrence of a first major cardiovascular event of the composite endpoint that includes:
• CV cardiovascular
• MI myocardial infarction
• a second, third, fourth and fifth major cardiovascular event e.g., occurrence of CV death, nonfatal MI, nonfatal stroke, coronary revascularization, and unstable angina determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization after a first occurrence of any of same;
• CHF congestive heart failure
• LDL-C low-density lipoprotein cholesterol
• HDL-C high-density lipoprotein cholesterol
• VLDL-C very low- density lipoprotein cholesterol
• apo B apoliporpotein B
• hs-CRP high-sensitivity C-reactive protein
• hsTnT high-sensitivity troponin
• the population for this study is men and women >45 years of age with established CVD, or men and women >50 years of age with diabetes in combination with one additional risk factor for CVD.
• all patients will have atherogenic dyslipidemia defined as on treatment for hypercholesterolemia (but at treatment goal for LDL-C, by treatment with a statin) and hypertriglyceridemia. More details are listed in the inclusion criteria.
• This study consists of the following study periods: [0095] Screening Period: During the screening period, patients will be evaluated for inclusion/exclusion criteria.
• Patients not eligible for participation in the study based on the study procedures on Visit 1 may possibly become eligible in the next 28 days: these patients may return at the discretion of the investigator for a second optional screening visit (Visit 1.1) at which time the procedures needed for re-evaluation of the previously failed inclusion/exclusion criteria will be repeated.
• This case includes, for example, patients who are started on a statin at Visit 1, whose statin dose is changed at Visit 1, and/or needed to wash out non-statin lipid-altering medications. The following applies for these patients:
• patients will need to meet all inclusion/exclusion criteria before they can be randomized. Patients who are not eligible for participation after the screening period (based on study procedures at Visit 1 and/or Visit 1.1) may return at a later date for rescreening. These patients will need to re-start with all procedures starting with Visit 1. This includes patients who need more time to stabilize one or more conditions or therapies (for example: statin, antidiabetic, antihypertensive, thyroid hormone, HIV-protease inhibitor therapy).
• statin for example: statin, antidiabetic, antihypertensive, thyroid hormone, HIV-protease inhibitor therapy.
• Treatment/Follow-Up Period Within 42 days after the first screening visit (Visit 1) or within 60 days after the first screening visit (Visit 1) for those patients that have a second screening visit (Visit 1.1), eligible patients will enter the
• the estimated study duration includes a planned 18-month enrollment period followed by a follow-up period of approximately 3.5 years in expected duration (approximately 5 years in total). Patients will be randomized at different times during the enrollment period but will all end the study at the same date (study end date). It is planned that all randomized patients will receive study medication and be followed-up until the study end date. This is an event-driven trial and patients will continue in the trial if the trial runs longer than expected, or will terminate earlier if the trial runs shorter than expected.
• the total duration of the trial is based on a median 4-year follow-up period across patients. The first patient randomized would be followed for 4.75 years (the longest individual follow-up duration), and the last patient randomized would be followed for 3.25 year (the shortest individual follow-up duration).
• Group 1 AMR101 4 g daily (four 1000 mg capsules daily)
• Group 2 placebo (four capsules daily)
• the four AMR101 or placebo capsules daily will be taken as two capsules in the morning and two capsules in the evening (twice-per-day dosing regimen).
• Participants will be assigned to treatment groups stratified by CV risk category, use of ezetimibe and by geographical region (Westernized, Eastern
• CV Risk Category 1 patients with established CVD defined in the inclusion criteria. Patients with diabetes and established CVD are included in this category.
• CV Risk Category 2 patients with diabetes and at least one additional risk factor for CVD, but no established CVD.
• CV Risk Category 1 Approximately 70% of randomized patients will be in the CV Risk Category 1 and approximately 30% of randomized patients will be in the CV Risk Category 2.
• Enrollment with patients of a CV risk category will be stopped when the planned number of patients in that risk category is reached.
• LDL-C >40 mg/dL (1.04 mmol/L) and ⁇ 100 mg/dL (2.60 mmol/L) and on stable therapy with a statin (with or without ezetimibe) for at least 4 weeks prior to the LDL-C/TG baseline qualifying measurements for randomization
• Stable therapy is defined as the same daily dose of the same statin for at least 28 days before the lipid qualification measurements (TG and LDL-C) and, if applicable, the same daily dose of ezetimibe for at least 28 days before the lipid qualification measurements (TG and LDL-C).
• Patients who have their statin therapy or use of ezetimibe initiated at Visit 1, or have their statin, statin dose and/or ezetimibe dose changed at Visit 1, will need to go through a stabilization period of at least 28 days since initiation/change and have their qualifying lipid measurements measured (TG and LDL-C) after the washout period (at Visit 1.1).
• Statins may be administered with or without ezetimibe.
• CV Risk Category 1 Either having established CVD (in CV Risk Category 1) or at high risk for CVD (in CV Risk Category 2).
• the CV risk categories are defined as follows:
• CV Risk Category 1 defined as men and women >45 years of age with one or more of the following:
• CAD Documented coronary artery disease
• CV Risk Category 2 defined as patients with:
• Diabetes mellitus Type 1 or Type 2 requiring treatment with medication AND
• Hs-CRP >3.00 mg/L (0.3 mg/dL);
• Renal dysfunction CrCL >30 and ⁇ 60 mL/min (>0.50 and ⁇ 1.00 mL/sec);
• Retinopathy defined as any of the following: non-proliferative retinopathy, preproliferative retinopathy, proliferative retinopathy, maculopathy, advanced diabetic eye disease or a history of photocoagulation;
• Micro- or macroalbuminuria is defined as either a positive micral or other strip test (may be obtained from medical records), an albumin creatinine ratio >2.5 mg/mmol or an albumin excretion rate on timed collection >20 mg/min all on at least two successive occasions; macroalbuminuria, defined as albustix or other dipstick evidence of gross proteinuria, an albumin creatinine ratio >25 mg/mmol or an albumin excretion rate on timed collection >200 mg/min all on at least two successive occasions;
• ABI ⁇ 0.9 without symptoms of intermittent claudication patients with ABI ⁇ 0.9 with symptoms of intermittent claudication are counted under CV Risk Category
• Women may be enrolled if all 3 of the following criteria are met:
• FSH follicle-stimulating hormone
• Active severe liver disease evaluationated at Visit 1: cirrhosis, active hepatitis, ALT or AST >3 x ULN, or biliary obstruction with hyperbilirubinemia (total bilirubin >2 x ULN).
• Planned coronary intervention such as stent placement or heart bypass
• Patients can be (re)evaluated for participation in the trial (starting with Visit 1.1) after their recovery from the intervention/ surgery.
• Malabsorption syndrome and/or chronic diarrhea are considered to have malabsorption, hence are excluded; patients who have undergone gastric banding are allowed to enter the trial).
• Non-study drug related, non-statin, lipid-altering medications, supplements or foods :
• Patients are excluded if they used niacin >200 mg/day or fibrates during the screening period (after Visit 1) and/or plan to use during the study; patients who are taking niacin >200 mg/day or fibrates during the last 28 days before Visit 1 need to go through washout of at least 28 days after their last use and have their qualifying lipids measured (TG and LDL-C) after the washout period (Visit 1.1);
• Patients are excluded if they use dietary supplements containing omega-3 fatty acids (e.g., flaxseed, fish, krill, or algal oils) during the screening period (after Visit 1) and/or plan to use during the treatment/follow-up period of the study.
• omega-3 fatty acids e.g., flaxseed, fish, krill, or algal oils
• patients who are taking >300 mg/day omega-3 fatty acids (combined amount of EPA and DHA) within 28 days before Visit 1 (except patients in The Netherlands), need to go through a washout period of at least 28 days since their last use and have their qualifying lipid measurements measured (TG and LDL-C) after the washout period (at Visit 1.1);
• Patients are excluded if they use bile acid sequestrants during the screening period (after Visit 1) and/or plan to use during the treatment/follow-up period of the study.
• patients who are taking bile acid sequestrants within 7 days before Visit 1 need to go through a washout period of at least 7 days since their last use and have their qualifying lipid measurements measured (TG and LDL-C) after the washout period (at Visit 1.1);
• a unit of alcohol is defined as a 12-ounce (350 mL) beer, 5-ounce (150 mL) wine, or 1.5-ounce (45 mL) of 80-proof alcohol for drinks.
• Visit 2 participation after Visit 1 because they meet all inclusion criterion and none of the exclusion criteria, may return to the Research Site for Visit 2 to be randomized and to start the treatment/follow-up period of the study. For these patients, Visit 2 will occur soon after Visit 1.
• Visit 1.1 Patients, who do not qualify at Visit 1, may return to the Research Site for a second qualifying visit (Visit 1.1) at the discretion of the investigator.
• Visit 1.1 procedures that caused failure of eligibility at Visit 1 will be repeated.
• Patients will be eligible for randomization after Visit 1.1 if they meet all inclusion criteria and if they no longer fail the exclusion criteria. If patients are evaluated at Visit 1.1 and qualify for randomization based on the repeated procedures at Visit 1.1, they need to be randomized within 60 days after Visit 1.
• Visit 1.1 will be mandatory at least 28 days after Visit 1 in order to check eligibility. These are patients who at Visit 1 started treatment with a statin, changed their statin, changed the daily dose of their statin, started to washout prohibited medications or started a stabilization period with certain medications (see inclusion/exclusion criteria for details). Any of these changes at Visit 1 may affect the qualifying lipid levels and therefore, patients will need to have Visit 1.1 to determine whether they qualify based on lipid level requirements (TG and LDL-C) determined at Visit 1. Other procedures that caused failure of eligibility at Visit 1 will also be repeated at Visit 1.1.
• TG and LDL-C lipid level requirements
• Visit 3 (Day 120; ⁇ 4 Months)
• Visit 4 Day 360 ⁇ 10; Visit 5: Day 720 ⁇ 10; Visit 6: Day 1080 ⁇ 10; and Visit 7: Day 1440 ⁇ 10, the following procedures will be performed:
• the end date of the study is expected for Day 1800 but the actual end date will be dependent on the determination of the study end date by the DMC.
• the study end date is determined to be when approximately 1612 primary efficacy events have occurred. If the actual study end date is later than the expected end date, additional visits will be planned between Visit 7 and the Last Visit with a maximum of 360 ⁇ 10 days between visits. If the actual study end date is sooner than the expected end date, fewer visits will occur, and the last visit (See Section 6.1.2.5) will occur sooner.
• the investigator must review and sign all laboratory test reports. At screening, patients who have laboratory values that are outside the exclusionary limits specified in the exclusion criteria may not be enrolled in the study (patients can be considered for the study if values are classified as not clinically significant by the investigator). After randomization, the investigator will be notified if laboratory values are outside of their normal range. In this case, the investigator will be required to conduct clinically appropriate follow-up procedures.
• the safety laboratory tests include: [0344] Hematology with complete blood count (CBC), including RBC, hemoglobin (Hgb), hematocrit (Hct), white cell blood count (WBC), white cell differential, and platelet count
• Biochemistry panel including total protein, albumin, alkaline phosphatase, alanine aminotransferase (ALT/SGPT), aspartate aminotransferase (AST/SGOT), total bilirubin, glucose, calcium, electrolytes (sodium, potassium, chloride), blood urea nitrogen (BUN), serum creatinine, uric acid, creatine kinase, and HbAlc.
• the fasting lipid panel includes: TG, TC, LDL-C, HDL-C, non-HDL-C, and VLDL-C.
• LDL-C will be calculated using the Friedewald equation.
• Direct LDL-C will be used if at the same visit TG >400 mg/dL (4.52 mmol/L).
• LDL-C inclusion criterion LDL-C qualifying measurements for randomization
• LDL-C will be measured by Direct LDL Cholesterol or by Preparative Ultracentrifugation if at the same visit TG >400 mg/dL (4.52 mmol/L).
• LDL-C will be measured by Preparative Ultracentrifugation. These Preparative Ultracentrifugation LDL-C measurements will be used in the statistical analysis including the calculation of the percent change from baseline (1 year versus baseline).
• a fasting blood sample will be stored for future genetic testing at the discretion of the sponsor. The specifics of this test will be determined at a later date. This sample is optional as local regulations may prohibit genetic samples to be collected or shipped outside the country, or patients may not consent.
• Research on genetic testing will look for links between genes and certain diseases, including their treatment(s) such as medicines and medical care.
• the blood samples will be collected in the study center with the regular protocol-required labs.
• Each patient tube with sample for genetic testing will be labeled with patient number only.
• the site will maintain a Subject Code Identification List for cross-reference. The patient number does not contain any identifiable information (i.e. Patient initials, date of birth, etc).
• Un-analyzed samples will be stored frozen by the sponsor for a period of up to 2 years following the end of the study, at which time they will be destroyed. If samples are tested, results will not be reported to the patient, parents, relatives, or attending physician and will not be recorded in the patient's medical records. There will be no follow-up contact with the sites or patients regarding this sample.
• the subject can withdraw their consent for genetic testing at any time up to analysis, even after the sample has been obtained.
• the subject can notify the site in writing that they withdraw their consent for the genetic testing portion of the study, and it will be documented by the site in the subject chart, as well as captured in the CRF.
• the lab will be notified to pull the sample and destroy it.
• the biomarker assays include: hs-CRP, Apo B and hsTnT.
• Additional laboratory tests include:
• a urine pregnancy test will be administered to women of childbearing potential at certain visits as listed in schedule of procedures (Table 1). The urine pregnancy tests will be performed at the Research Site utilizing marketed test kits, or at a certified clinical laboratory.
• a fasting blood sample (12 mL) for archiving This sample will be collected only at sites in countries where allowed by local regulations and at sites for which approved by the IRB or IEC.
• the plasma from the archiving sample will be stored frozen in 2 separate equal aliquots, and will be used at the Sponsor's discretion to perform repeat analyses described in the protocol or to perform other tests related to cardiovascular health.
• Critical lab values are values that may warrant medical intervention to avoid possible harm to a patient.
• Critical lab values will be defined in the Laboratory Manual for the study, and the Research Site will be notified of the occurrence of a critical lab value (critical high or critical low) by a special annotation (flag) in the laboratory reports provided to the Research Sites.
• TG values are confirmed critically high, patients may be discontinued from study drug with the option to remain on study.
• the investigator should use the best clinical judgment for each patient which could include the use of approved TG- lowering medications after patients have been discontinued from study drug.
• the investigator may need to take appropriate medical action which could include: reinforce/intensify therapeutic lifestyle changes (including diet and physical activity), increase the dose of the present statin therapy, add ezetimibe, or prescribe a more potent statin to lower LDL-C.
• the investigator should use the best clinical judgment for each patient.
• Demographic information including day, month, and year of birth, race, and gender will be collected for all patients.
• Vital signs include systolic and diastolic blood pressure, heart rate, respiratory rate, and body temperature. Blood pressure will be measured using a standardized process:
• Patient should sit for >5 minutes with feet flat on the floor and measurement arm supported so that the midpoint of the manometer cuff is at heart level.
• Blood pressure should be recorded to the nearest 2 mmHg mark on the manometer or to the nearest whole number on an automatic device. A blood pressure reading should be repeated 1 to 2 minutes later, and the second reading should also be recorded to the nearest 2 mmHg mark.
• a physical examination must include source documentation of general appearance, skin, and specific head and neck, heart, lung, abdomen, extremities, and neuromuscular assessments.
• Waist circumference will be measured with a tape measure, as follows: Start at the top of the hip bone then bring the tape measure all the way around - level with the navel. Make sure the tape measure is snug, but without compressing the skin, and that it is parallel with the floor.
• ECG Electrocardiogram
• ECGs standard 12-lead
• Site personnel should make every attempt to perform a patient's ECG using the same equipment at each visit.
• ECGs will be reviewed by the site for the detection of silent MI. Silent Mis will be sent for event adjudication.
• Eligible study patients will be randomly assigned on Day 0 to one of the 2 treatment groups. Patients in each group will receive either 4 g/day AMR101 or placebo for up to 4.75 years (4 years planned median treatment duration) according to Table 2. [0383] The daily dose of study drug is 4 capsules per day taken as two capsules take on two occasions per day (2 capsules given twice daily).
• a unique patient identification number (patient number) will be established for each patient at each site. The patient number will be used to identify the patient throughout the study and will be entered on all documentation. If a patient is not eligible to receive treatment, or if a patient discontinues from the study, the patient number cannot be reassigned to another patient. The patient number will be used to assign patients to one of the 2 treatment groups according to the randomization schedule.
• the investigator may request the patient's treatment assignment for unblinding. Prior to unblinding the patient's individual treatment assignment, the investigator should assess the relationship of an adverse event to the administration of the study drug (Yes or No). If the blind is broken for any reason, the investigator must record the date and reason for breaking the blind on the appropriate Case Report Form (CRF) and source documents.
• CRF Case Report Form
• niacin >200 mg/day
• omega-3 fatty acids e.g., flaxseed, fish, krill, or algal oils
• Statins may be administered with or without ezetimibe.
• simvastatin 80 mg be used only in patients who have been taking this dose for 12 months or more and have not experienced any muscle toxicity.
• FDA Drug Safety Communication Ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury.
• Excessive alcohol consumption is on average 2 units of alcohol per day or drinking 5 units or more for men or 4 units or more for women in any one hour (episodic excessive drinking or binge drinking).
• a unit of alcohol is defined as a 12-ounce (350 mL) beer, 5-ounce (150 mL) wine, or 1.5- ounce (45 mL) of 80-proof alcohol for drinks.
• the Sponsor will supply sufficient quantities of AMR101 1000 mg capsules and placebo capsules to allow for completion of the study. The lot numbers of the drugs supplied will be recorded in the final study report.
• AMR101 1000 mg and placebo capsules are provided in liquid- filled, oblong, gelatin capsules. Each capsule is filled with a clear liquid (colorless to pale yellow in color). The capsules are approximately 25.5 mm in length with a diameter of approximately 9.5 mm.
• Study medication will be packaged in high-density polyethylene bottles. Labeling and packaging will be performed according to GMP guidelines and all applicable country-specific requirements. The bottles will be numbered for each patient based on the randomization schedule. The patient randomization number assigned by IWR or a designee of the Sponsor for the study (if no IWR system is used), will correspond to the number on the bottles. The bottle number for each patient will be recorded in the Electronic Data Capture (EDC) system for the study.
• EDC Electronic Data Capture
• Visit 2 At Visit 2 (Day 0), patients will be assigned study drug according to their treatment group determined by the randomization schedule. Once assigned to a treatment group, patients will receive study drug supplies. At each visit, patients will bring unused drug supplies dispensed to them earlier. From the drug supplies assigned to each patient, site personnel will administer drug while the patients are at the Research Site.
• the investigator or designee must contact the IWR system or a designee of the Sponsor for the study (if no IWR system is used) when any unscheduled replacements of study medication are needed.
• study drugs must be stored at room temperature, 68°F to 77°F (20°C to 25°C). Do not allow storage temperature to go below 59°F (15°C) or above 86°F (30°C). Store in the original package.
• Study drugs must be stored in a pharmacy or locked and secure storage facility, accessible only to those individuals authorized by the investigator to dispense the drug. The investigator or designee will keep accurate dispensing records. At the conclusion of the study, study site personnel will account for all used and unused study drug. Any unused study drug will be destroyed. The investigator agrees not to distribute study drug to any patient, except those patients participating in the study.
• the primary endpoint and the majority of the secondary and tertiary endpoints are based on clinical events related to CVD and mortality. All events occurring between randomization and the study end date (inclusive) must be recorded. Only adjudicated events will be included in the final analyses. Further details on the assessment of clinical events and their definitions will be found in the CEC charter.
• Nonfatal MI including silent MI; ECGs will be performed annually for the detection of silent Mis
• the composite of death from CV causes, nonfatal MI, coronary revascularization, unstable angina determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization, nonfatal stroke, or peripheral CVD requiring intervention, angioplasty, bypass surgery, or aneurysm repair.
• the composite of death from CV causes, nonfatal MI, coronary revascularization, unstable angina determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization, peripheral CVD requiring intervention, or cardiac arrhythmia requiring hospitalization;
• the composite of death from CV causes, nonfatal MI, coronary revascularization, or unstable angina determined to be caused by myocardial ischemia by invasive/non-invasive testing and requiring emergent hospitalization;
• the second, third, fourth, and fifth major CV event of the primary composite endpoint may occur in any order.
• the first occurrence of this type of event will be counted in each patient.
• the first occurrence of any of the event types included in the composite will be counted in each patient (except when stated otherwise, for the second, third, fourth, and fifth major CV event).
• Safety assessments will include adverse events, clinical laboratory measurements (chemistry, hematology), 12-lead ECGs, vital signs (systolic and diastolic blood pressure, heart rate, respiratory rate, and body temperature), and physical examinations as per Study Procedures/Table 1.
• An adverse event is defined as any untoward medical occurrence, which does not necessarily have a causal relationship with the medication under
• An adverse event can therefore be any unfavorable and/or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of an investigational medication product, whether or not related to the investigational medication product. All adverse events, including observed or volunteered problems, complaints, or symptoms, are to be recorded on the appropriate CRF. Each adverse event is to be evaluated for duration, intensity, and causal relationship with the study medication or other factors.
• Adverse events which include clinical laboratory test variables, will be monitored from the time of informed consent until study participation is complete. Patients should be instructed to report any adverse event that they experience to the investigator. Beginning with Visit 2, investigators should assess for adverse events at each visit and record the event on the appropriate adverse event CRF.
• a specific disease or syndrome rather than individual associated signs and symptoms should be identified by the investigator and recorded on the CRF. However, if an observed or reported sign or symptom is not considered a component of a specific disease or syndrome by the investigator, it should be recorded as a separate adverse event on the CRF.
• the investigator will rate the severity (intensity) of each adverse event as mild, moderate, or severe, and will also categorize each adverse event as to its potential relationship to study drug using the categories of Yes or No.
• the event should occur after the study medication is given.
• the length of time from study medication exposure to event should be evaluated in the clinical context of the event.
• Clinical and/or preclinical data may indicate whether a particular response is likely to be a class effect.
• Exposure to physical and/or mental stresses may indicate whether a particular response is likely to be a class effect.
• Unexpected Adverse Events An unexpected adverse event is an adverse event either not previously reported or where the nature, seriousness, severity, or outcome is not consistent with the current Investigator's Brochure.
• a serious adverse event is defined as an adverse event that meets any of the following criteria:
• life-threatening in the definition of "serious” refers to an event in which the patient was at risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused death, if it were more severe.
• Important medical events that may not result in death, be life threatening, or require hospitalization may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed above.
• Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalizations, or the development of drug dependency.
• the investigator is required to submit SAE reports to the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) in accordance with local requirements. All investigators involved in studies using the same investigational medicinal product (IMP) will receive any Suspected Unexpected Serious Adverse Reaction (SUSAR) reports for onward submission to their local IRB as required. All reports sent to investigators will be blinded.
• IRS Institutional Review Board
• IEC Independent Ethics Committee
• the investigator must continue to follow the patient until the SAE has subsided, or until the condition becomes chronic in nature, stabilizes (in the case of persistent impairment), or the patient dies.
• the investigator must update the SAE form electronically in the EDC system for the study and submit any supporting documentation (e.g., laboratory test reports, patient discharge summary, or autopsy reports) to the Sponsor or designee via fax or email.
• the patient should be followed by the investigator until completion of the pregnancy. If the pregnancy ends for any reason before the anticipated date, the investigator should notify the Sponsor or designee. At the completion of the pregnancy, the investigator will document the outcome of the pregnancy. If the outcome of the pregnancy meets the criteria for immediate classification as an SAE (i.e., postpartum complication, spontaneous abortion, stillbirth, neonatal death, or congenital anomaly), the investigator should follow the procedures for reporting an SAE.
• SAE postpartum complication, spontaneous abortion, stillbirth, neonatal death, or congenital anomaly
• ALT 3x ULN
• bilirubin 1.5x ULN
• a TG value that is flagged as critically high i.e., >1000 mg/dL (11.29 mmol/L), and confirmed as critically high by a repeat measurement (new fasting blood sample) within 7 days.
• a patient may be discontinued from study drug (with the option to remain ODIS) and other lipid-altering medications may be (re)initiated.
• the TG value is flagged as >2000 mg/dL (22.58 mmol/L) then appropriate medical action can be taken by the investigator as soon as possible.
• ODIS Off Drug In Study
• the randomized population will include all patients who sign the informed consent form and are assigned a randomization number at Visit 2 (Day 0).
• the Intent-to-Treat (ITT) population will consist of all randomized patients who take at least one dose of study drug.
• the ITT population is the primary analysis population. All efficacy analyses will be performed on the ITT population.
• the per-protocol (PP) population will include all ITT patients without any major protocol deviations, and who had >80% compliance with study drug while on treatment (up to discontinuation for patients whose treatment is terminated early).
• the per-protocol efficacy analysis for CV events will be restricted to each patient's time on study drug plus 30 days thereafter.
• Summary statistics (mean, standard deviation, median, minimum and maximum) will be provided by treatment group for demographic characteristics (e.g., age, sex, race, and ethnicity) and baseline characteristics (e.g., body weight, height, and body mass index) in the ITT and PP populations.
• demographic characteristics e.g., age, sex, race, and ethnicity
• baseline characteristics e.g., body weight, height, and body mass index
• Demographic data and baseline characteristics will be compared among treatment groups for the ITT and PP population. Differences in demographic and baseline characteristics will be tested using a chi-square test (for categorical variables) or a 1-way analysis of variance model with treatment as a factor (for continuous variables). The p-values will be used as descriptive statistics, primarily as an assessment of the adequacy of randomization.
• the final compliance to study drug will be calculated as the percent of doses taken relative to doses scheduled to be taken. Overall percent compliance will be calculated per patient in the ITT and PP populations and summarized by treatment group using summary statistics (n, mean, standard deviation, median, minimum, and maximum).
• Concomitant therapies [0569] Concomitant medication/therapy verbatim terms will be coded using the latest version of the World Health Organization Drug Dictionary. The numbers and percentages of patients in each treatment group taking concomitant medications will be summarized by anatomic and therapeutic chemical classification and preferred term.
• Summary statistics (n, mean, standard deviation, median, minimum, and maximum) for the baseline and post-baseline measurements, the percent changes, or changes from baseline will be presented by treatment group and by visit for all efficacy variables to be analyzed.
• the summary statistics will include changes in body weight and body mass index from baseline by treatment group and by visit.
• the primary efficacy endpoint is the time from randomization to the first occurrence of any component of the composite of the following clinical events:
• the analysis of the primary efficacy endpoint will be performed using the log-rank test comparing the 2 treatment groups (AMRlOl and placebo) and including the stratification factor "CV risk category", use of ezetimibe and geographical region (Westernized, Eastern European, and Asia Pacific countries) (each as recorded in the IWR at the time of enrollment) as covariates. Treatment difference will be tested at alpha level of 0.0476 accounting for one interim efficacy analysis.
• the hazard ratio for treatment group (AMR101 vs. placebo) from a Cox proportional hazard model that includes the stratification factor will also be reported, along with the associated 95% confidence interval. Kaplan-Meier estimates from randomization to the time to the primary efficacy endpoint will be plotted.
• HbAi c >6.5%.
• the test should be performed in a laboratory using a method that is National Glycohemoglobin Standardization Program (NGSP) certified and standardized to the Diabetes Control and Complications Trial (DCCT) assay.
• NGSP National Glycohemoglobin Standardization Program
• DCCT Diabetes Control and Complications Trial
• FPG Fasting plasma glucose
• race (white and nonwhite, or any other subset with at least 10% of the total number of patients),
• statin intensity (statin type and regimen)
• One interim analysis will be performed for the primary efficacy endpoint using best available data (adjudicated events and site reported endpoints) based on data when approximately 60% of the total number of primary endpoint events is reached.
• Approximately 1612 primary efficacy endpoint events are planned to be observed during the trial, based on sample size calculation assumptions. Therefore, the interim analysis will occur after at least 967 primary efficacy endpoint events have been observed. According to this boundary, the critical p-value at the interim analysis has to be p ⁇ 0.0076, resulting in the final evaluation p-value of 0.0476.
• TEAEs treatment-emergent
• Treatment-emergent adverse events will be summarized by system organ class and preferred term, and by treatment. This will include overall incidence rates (regardless of severity and relationship to study drug), and incidence rates for moderate or severe adverse events. A summary of SAEs and adverse events leading to early discontinuation from the study will be presented through data listings.
• Safety laboratory tests and vital signs will be summarized by post-treatment change from baseline for each of the parameters using descriptive statistics by treatment group. Those patients with significant laboratory abnormalities will be identified in data listings. Additional safety parameters will be summarized in data listings.
• Sample size estimation is based on the assumption that the primary composite endpoint (time from randomization to the first occurrence of CV death, nonfatal MI, non- fatal stroke, coronary revascularization, or unstable angina requiring hospitalization) would be relatively reduced by 15%, from an event rate by 4 years of 23.6% in the placebo group to 20.5% in the AMR101 group. It is expected that a minimum of 1612 primary efficacy endpoint events will be required during the study. A total of approximately 6990 patients are needed to be able to detect this difference at 4.76% significance level (because of the interim analysis described in Section
• the 'sample size' is the number of events rather than the number of patients.
• the number of events that occur depends primarily on three factors: how many patients are enrolled, the combined group event rate, and how long the patients are followed. Because of the difficulty in predicting the combined event rate, the sponsor will monitor that event rate as the trial progresses. If the combined event rate is less than anticipated, either increasing the number of patients, extending the length of follow-up, or a balance of adjusting both factors may be necessary to achieve the sample size of 1612 events.
• the actual event rate based on pooled, blinded accumulation of primary efficacy endpoint events will be calculated and plotted. If those analyses suggest the number of patients with at least 1 adjudicated, primary event (and appropriately accounting for patients with potential primary events for which the adjudication process is then incomplete) is consistent with projections, then the study could continue toward the protocol-specified target enrollment of 7990 patients. However, if the number of such events appears less than, and inconsistent with projections, the Sponsor will consider (under blinded conditions) re-calculating the number of patients needed to achieve the target number of events within the desired timeline or extend the follow-up period.
• the Sponsor may, with documented approval of both the REDUCE-IT Steering Committee (SC) and the Data Monitoring Committee (DMC), extend enrollment to the revised target number without need for an additional protocol amendment. Under those conditions, all principal investigators, ethics committees, and regulatory authorities associated with the protocol will be promptly notified of the action. Should the projected increase in number of patients be more than 25% above the original 7990 target (i.e. more than 1998 additional patients) a formal protocol amendment will be initiated.
• SC REDUCE-IT Steering Committee
• DMC Data Monitoring Committee
• the actual number of patients randomized may vary from the target number (either original or revised) as a result of the inherent lag between the date the last patient started screening and the date the last patient was randomized.
• the Investigator must maintain all documents and records, originals or certified copies of original records, relating to the conduct of this trial, and necessary for the evaluation and reconstruction of the clinical trial.
• This documentation includes, but is not limited to protocol, CRFs, AE reports, patient source data (including records of patients, patient visit logs, clinical observations and findings), correspondence with health authorities and IRB, consent forms, inventory of study product, Investigator's curriculum vitae, monitor visit logs, laboratory reference ranges and laboratory certification or quality control procedures, and laboratory director curriculum vitae.
• the Investigator and affiliated institution should maintain the trial documents as required by the applicable regulations.
• the Investigator and affiliated institution should take measures to prevent accidental or premature destruction of documents.
• Clinical trial documents must be kept in the clinical site's archives indefinitely, unless written authorization is obtained from the Sponsor.
• the Sponsor and/or its designee(s) will perform quality control and quality assurance checks of all clinical trials that it sponsors. Before the enrollment of any patient in this study, the Sponsor or its designee will review with the investigator and site personnel the following documents: protocol, Investigator's Brochure, CRFs and procedures for their completion, the informed consent process, and the procedure for reporting SAEs. Site visits will be performed by the Sponsor and/or its designees. During these visits, information recorded on the CRFs will be verified against source documents and requests for clarification or correction may be made. After the CRF data is entered by the site, the Sponsor or designee will review for safety information, completeness, accuracy, and logical consistency. Computer programs that identify data inconsistencies may be used to help monitor the clinical trial. If necessary, requests for clarification or correction will be sent to investigators.
• the Sponsor agrees directly or through its designee(s) to be responsible for implementing and maintaining quality control and quality assurance systems with written standard operating procedures to ensure that trials are conducted and data are generated, documented, and reported in compliance with the protocol, accepted standards of Good Clinical Practice (GCP), International Conference on Harmonization (ICH) and other applicable regulations.
• GCP Good Clinical Practice
• ICH International Conference on Harmonization
• the end of the study will be at the time of the last patient-last visit of the follow-up period of the study.
• the IRB and IEC will be notified about the end of the study according to country-specific regulatory requirements.
• 42 days 1 may 0 120 360 720 1080 1440 1800
• Inclusion/exclusion criteria will be re-evaluated for selected study procedures that are performed atients failed to meet them at Visit 1. Height at first screening visit only.
• Vital signs including systolic and diastolic blood pressure (mmHg), heart rate, respiratory rate and body temperature. Participants must be seated for at least 5 minutes before assessments of vital signs.
• mmHg systolic and diastolic blood pressure
• the patients will fast of at least 10 hours before arriving at the Research Site, when all fasting blood samples will be obtained. After blood samples are obtained, patients will be given drug with food.
• Site personnel will contact each patient by telephone in-between Visit 2 and Visit 3 and between Visit 3 and Visit 4. After Visit 4 contact will be made every 3 months.
• the purpose of the contact is to collect information about efficacy events, adverse events, concomitant medications, confirm patient's current address and contact information and remind patients about taking their study medication and logistics for the next visit.
• the last visit (LV) may occur within 30 day after the study end date as determined by the DMC; the study end date is tentatively schedule for Day 1800 but the actual date as determined by the DMC may be different.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Organic Chemistry (AREA)
• Cardiology (AREA)
• Epidemiology (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Heart & Thoracic Surgery (AREA)
• Molecular Biology (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Emergency Medicine (AREA)
• Analytical Chemistry (AREA)
• Physics & Mathematics (AREA)
• Pathology (AREA)
• Diabetes (AREA)
• Food Science & Technology (AREA)
• Microbiology (AREA)
• Biochemistry (AREA)
• Cell Biology (AREA)
• Biotechnology (AREA)
• General Physics & Mathematics (AREA)
• Obesity (AREA)
• Vascular Medicine (AREA)
• Biophysics (AREA)
• Child & Adolescent Psychology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Hospice & Palliative Care (AREA)

Priority Applications (62)

Applications Claiming Priority (2)

Related Child Applications (3)

Publications (2)

Family

ID=49784037

Family Applications (1)

Country Status (42)

Cited By (30)

Families Citing this family (15)

Family Cites Families (320)

• 2013
  • 2013-06-28 CN CN201380040239.5A patent/CN104582698A/zh active Pending
  • 2013-06-28 SM SM20250326T patent/SMT202500326T1/it unknown
  • 2013-06-28 HR HRP20241269TT patent/HRP20241269T1/hr unknown
  • 2013-06-28 BR BR112014032905-2A patent/BR112014032905B1/pt active IP Right Grant
  • 2013-06-28 SM SM20210220T patent/SMT202100220T1/it unknown
  • 2013-06-28 SG SG10201913646PA patent/SG10201913646PA/en unknown
  • 2013-06-28 ES ES24152359T patent/ES3040240T3/es active Active
  • 2013-06-28 FI FIEP20201864.4T patent/FI3815684T3/fi active
  • 2013-06-28 UA UAA201804458A patent/UA128280C2/uk unknown
  • 2013-06-28 LT LTEP17206714.2T patent/LT3363433T/lt unknown
  • 2013-06-28 SG SG10201913645RA patent/SG10201913645RA/en unknown
  • 2013-06-28 MX MX2020002907A patent/MX392694B/es unknown
  • 2013-06-28 ES ES24152348T patent/ES3040261T3/es active Active
  • 2013-06-28 MY MYPI2014703981A patent/MY187464A/en unknown
  • 2013-06-28 HR HRP20251049TT patent/HRP20251049T1/hr unknown
  • 2013-06-28 FI FIEP24152359.6T patent/FI4338805T3/fi active
  • 2013-06-28 IL IL275396A patent/IL275396B2/en unknown
  • 2013-06-28 SI SI201332108T patent/SI4338805T1/sl unknown
  • 2013-06-28 MX MX2020013922A patent/MX394763B/es unknown
  • 2013-06-28 PL PL24152348.9T patent/PL4342546T3/pl unknown
  • 2013-06-28 PL PL20201864.4T patent/PL3815684T3/pl unknown
  • 2013-06-28 PL PL17206714T patent/PL3363433T3/pl unknown
  • 2013-06-28 WO PCT/US2013/048559 patent/WO2014005013A2/en not_active Ceased
  • 2013-06-28 GE GEAP201313705A patent/GEP201706768B/en unknown
  • 2013-06-28 NZ NZ743714A patent/NZ743714A/en unknown
  • 2013-06-28 PT PT241523596T patent/PT4338805T/pt unknown
  • 2013-06-28 HU HUE24152359A patent/HUE072535T2/hu unknown
  • 2013-06-28 ES ES17206714T patent/ES2846176T3/es active Active
  • 2013-06-28 CA CA3067012A patent/CA3067012C/en active Active
  • 2013-06-28 PT PT202018644T patent/PT3815684T/pt unknown
  • 2013-06-28 ES ES20201864T patent/ES2993235T3/es active Active
  • 2013-06-28 PL PL24152359.6T patent/PL4338805T3/pl unknown
  • 2013-06-28 LT LTEP24152359.6T patent/LT4338805T/lt unknown
  • 2013-06-28 HU HUE20201864A patent/HUE069516T2/hu unknown
  • 2013-06-28 CA CA2877514A patent/CA2877514C/en active Active
  • 2013-06-28 SI SI201332093T patent/SI3815684T1/sl unknown
  • 2013-06-28 RS RS20241044A patent/RS65970B1/sr unknown
  • 2013-06-28 EP EP24152359.6A patent/EP4338805B1/en active Active
  • 2013-06-28 IL IL313596A patent/IL313596A/en unknown
  • 2013-06-28 KR KR1020157002383A patent/KR20150036252A/ko not_active Ceased
  • 2013-06-28 JP JP2015520566A patent/JP2015522029A/ja active Pending
  • 2013-06-28 DK DK24152359.6T patent/DK4338805T3/da active
  • 2013-06-28 EP EP20201864.4A patent/EP3815684B1/en active Active
  • 2013-06-28 DK DK24152348.9T patent/DK4342546T3/da active
  • 2013-06-28 EA EA201890380A patent/EA039108B1/ru unknown
  • 2013-06-28 SM SM20240504T patent/SMT202400504T1/it unknown
  • 2013-06-28 RS RS20250866A patent/RS67162B1/sr unknown
  • 2013-06-28 NZ NZ703267A patent/NZ703267A/en unknown
  • 2013-06-28 SG SG10201913647QA patent/SG10201913647QA/en unknown
  • 2013-06-28 NZ NZ743706A patent/NZ743706A/en unknown
  • 2013-06-28 SI SI201331859T patent/SI3363433T1/sl unknown
  • 2013-06-28 MX MX2015000138A patent/MX378496B/es unknown
  • 2013-06-28 EP EP25168482.5A patent/EP4556073A3/en active Pending
  • 2013-06-28 LT LTEP20201864.4T patent/LT3815684T/lt unknown
  • 2013-06-28 PE PE2014002521A patent/PE20150770A1/es not_active Application Discontinuation
  • 2013-06-28 RS RS20210245A patent/RS61557B1/sr unknown
  • 2013-06-28 DK DK20201864.4T patent/DK3815684T3/da active
  • 2013-06-28 UA UAA201500699A patent/UA118015C2/uk unknown
  • 2013-06-28 RS RS20250865A patent/RS67161B1/sr unknown
  • 2013-06-28 SI SI201332109T patent/SI4342546T1/sl unknown
  • 2013-06-28 AU AU2013282394A patent/AU2013282394B2/en active Active
  • 2013-06-28 SG SG11201408769QA patent/SG11201408769QA/en unknown
  • 2013-06-28 MX MX2020008890A patent/MX394764B/es unknown
  • 2013-06-28 SM SM20250325T patent/SMT202500325T1/it unknown
  • 2013-06-28 EP EP24152348.9A patent/EP4342546B1/en active Active
  • 2013-06-28 DK DK17206714.2T patent/DK3363433T3/da active
  • 2013-06-28 HU HUE24152348A patent/HUE072482T2/hu unknown
  • 2013-06-28 US US14/411,815 patent/US9603826B2/en active Active
  • 2013-06-28 SG SG10201703867RA patent/SG10201703867RA/en unknown
  • 2013-06-28 HR HRP20251052TT patent/HRP20251052T1/hr unknown
  • 2013-06-28 HK HK15104816.7A patent/HK1204271A1/xx unknown
  • 2013-06-28 HU HUE17206714A patent/HUE053111T2/hu unknown
  • 2013-06-28 MA MA50258A patent/MA50258B2/fr unknown
  • 2013-06-28 CN CN202010737992.1A patent/CN111840268A/zh active Pending
  • 2013-06-28 EP EP17206714.2A patent/EP3363433B1/en not_active Revoked
  • 2013-06-28 CN CN202010032201.5A patent/CN111166736A/zh active Pending
  • 2013-06-28 EP EP13809488.3A patent/EP2866801A4/en not_active Withdrawn
  • 2013-06-28 NZ NZ737380A patent/NZ737380A/en unknown
  • 2013-06-28 EA EA201500069A patent/EA029988B1/ru unknown
  • 2013-06-28 PT PT172067142T patent/PT3363433T/pt unknown
  • 2013-06-28 CN CN202010748045.2A patent/CN111840269A/zh active Pending
  • 2013-06-28 CA CA3067008A patent/CA3067008C/en active Active
  • 2013-06-28 MX MX2020013933A patent/MX2020013933A/es unknown
  • 2013-06-28 LT LTEP24152348.9T patent/LT4342546T/lt unknown
  • 2013-06-28 NZ NZ727849A patent/NZ727849A/en unknown
  • 2013-06-28 FI FIEP24152348.9T patent/FI4342546T3/fi active
  • 2013-06-28 PT PT241523489T patent/PT4342546T/pt unknown
• 2014
  • 2014-12-18 CR CR20140591A patent/CR20140591A/es unknown
  • 2014-12-21 IL IL236376A patent/IL236376B/en active IP Right Grant
  • 2014-12-22 PH PH12014502849A patent/PH12014502849A1/en unknown
  • 2014-12-26 CL CL2014003534A patent/CL2014003534A1/es unknown
  • 2014-12-26 DO DO2014000301A patent/DOP2014000301A/es unknown
  • 2014-12-29 TN TN2014000540A patent/TN2014000540A1/fr unknown
  • 2014-12-29 CU CUP2014000151A patent/CU20140151A7/es unknown
  • 2014-12-29 NI NI201400155A patent/NI201400155A/es unknown
• 2015
  • 2015-01-06 ZA ZA2015/00040A patent/ZA201500040B/en unknown
  • 2015-01-07 MX MX2022010507A patent/MX2022010507A/es unknown
  • 2015-01-27 EC ECIEPI20152815A patent/ECSP15002815A/es unknown
  • 2015-01-28 CO CO15017153A patent/CO7190236A2/es unknown
• 2016
  • 2016-10-25 US US15/333,968 patent/US9623001B2/en active Active
  • 2016-10-25 US US15/333,991 patent/US9610272B2/en active Active
• 2017
  • 2017-01-18 US US15/409,244 patent/US9693984B2/en active Active
  • 2017-02-02 US US15/422,634 patent/US9693985B2/en active Active
  • 2017-02-08 US US15/427,238 patent/US9693986B2/en active Active
  • 2017-05-26 US US15/607,011 patent/US9918954B2/en active Active
  • 2017-05-26 US US15/607,050 patent/US20170258754A1/en not_active Abandoned
  • 2017-05-26 US US15/607,084 patent/US9918955B2/en active Active
• 2018
  • 2018-02-01 US US15/886,422 patent/US10016386B2/en active Active
  • 2018-06-12 US US16/005,969 patent/US10278936B2/en active Active
  • 2018-06-12 US US16/006,003 patent/US10278937B2/en active Active
  • 2018-06-12 US US16/005,852 patent/US10278935B2/en active Active
  • 2018-06-21 AU AU2018204499A patent/AU2018204499B2/en active Active
  • 2018-08-01 JP JP2018144666A patent/JP2018184463A/ja active Pending
  • 2018-10-10 US US16/156,879 patent/US10278938B2/en active Active
  • 2018-10-16 US US16/162,115 patent/US10278939B2/en active Active
  • 2018-11-19 US US16/195,126 patent/US20190083445A1/en not_active Abandoned
• 2019
  • 2019-02-27 US US16/287,157 patent/US10383840B2/en active Active
  • 2019-07-03 US US16/502,621 patent/US10555924B2/en active Active
  • 2019-07-29 US US16/525,388 patent/US10792270B2/en active Active
  • 2019-10-11 US US16/599,412 patent/US10555925B1/en active Active
  • 2019-10-11 US US16/599,374 patent/US10568861B1/en active Active
  • 2019-11-06 US US16/676,055 patent/US20200069632A1/en not_active Abandoned
  • 2019-11-15 US US16/685,628 patent/US10576054B1/en active Active
  • 2019-12-03 US US16/702,087 patent/US20200113864A1/en not_active Abandoned
  • 2019-12-10 JP JP2019222599A patent/JP2020073492A/ja active Pending
• 2020
  • 2020-01-29 US US16/775,521 patent/US10894028B2/en active Active
  • 2020-12-22 AU AU2020294210A patent/AU2020294210B2/en active Active
• 2021
  • 2021-01-27 CY CY20211100058T patent/CY1123749T1/el unknown
  • 2021-02-24 HR HRP20210309TT patent/HRP20210309T1/hr unknown
• 2023
  • 2023-06-30 US US18/217,045 patent/US20230338323A1/en not_active Abandoned